Response rates and survival times
| n | Treatment duration, months, median (range) | Response*, n (%) | Survival, months, median (95% CI) | |||||||
| ORR | DCR | SD | PR | mDOR (months) | PFS | irPFS | OS | |||
| All patients | 26 | 4.8 (0.9–15.0) | 5 (19.2) | 14 (53.8) | 9 (34.6) | 5 (19.2) | 6.0 | 2.9 (1.8 to 5.7) | 2.9 (1.8 to 5.9) | 19.2 (10.0 to 27.9) |
| Cohort 08 | 12 | 2.45 (0.9–12.6) | 1 (8.3) | 6 (50.0) | 5 (41.7) | 1 (8.3) | 3.1 | 2.8 (1.4 to 5.7) | 2.8 (1.4 to 5.9) | 19.2 (3.8 to 27.9) |
| Cohort 09 | 14 | 6.05 (1.4–15.0) | 4 (28.6) | 8 (57.1) | 4 (28.6) | 4 (28.6) | 7.8 | 3.0 (1.8 to NA) | 3.0 (1.8 to NA) | 17.4 (9.7 to 40.2) |
| Patients with ALM | 18 | – | – | – | – | – | – | 3.0 (1.8 to 5.7) | 3.0 (1.8 to 5.9) | 19.2 (9.7 to 30.0) |
*According to RECIST V.1.1.
ALM, acral lentiginous melanoma; DCR, disease control rate; irPFS, immune-related progression-free survival; mDOR, median duration of response; NA, not available; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.